Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The hypothesis is that there is no difference in persistency between Xalacom and the alternative fixed dose combination products (Duotrav and Ganfort) over a 12 month period.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Criteria

Inclusion Criteria:

• Patients who had received a prescription for either Xalacom, Ganfort and DuoTrav

• Greater than 18 years old

• Diagnosed with glaucoma or ocular hypertension

• Registered at the primary care practice for > 12 months

Exclusion Criteria:

• None